Hormonal

Obese patients with type 2 diabetes or insulin resistance benefit from a low-carbohydrate diet combined with a GLP-1 agonist.

Clinicians should consider recommending a low-carbohydrate diet with GLP-1 agonists for obese patients with type 2 diabetes.

StrongSupportsmedium confidence

Source linkage for this finding is being attached.

Related findings · Hormonal

Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →